Pilot trial found medical cannabis feasible and potentially helpful for pain in stage IV cancer patients on opioids
In a pilot RCT of 30 stage IV cancer patients on opioids, medical cannabis was well-tolerated and a higher proportion of early cannabis users achieved reduced opioid use and improved pain control compared to standard care.
Quick Facts
What This Study Found
High enrollment interest (36% of eligible patients enrolled). Average daily doses at 3 months were 34 mg THC and 17 mg CBD. A higher proportion of early cannabis users achieved opioid reduction and improved pain control. No serious safety issues. High patient satisfaction.
Key Numbers
Enrolled: 30. Randomized 1:1. Enrollment rate: 36% of eligible. Mean daily THC: 34 mg. Mean daily CBD: 17 mg. Follow-up: 3 months. No serious adverse events.
How They Did This
Pilot RCT randomizing 30 stage IV cancer patients requiring opioids to early cannabis (n=15, immediate medical cannabis via state program) vs. delayed start cannabis (n=15, standard care for 3 months). Licensed pharmacists at dispensaries guided dosing.
Why This Research Matters
This study demonstrates that conducting randomized cannabis trials through state programs is feasible, a critical step toward building the rigorous evidence base needed for clinical guidelines.
The Bigger Picture
The feasibility of conducting RCTs through state cannabis programs opens a pathway for larger, more definitive trials that have been difficult to conduct under federal restrictions.
What This Study Doesn't Tell Us
Very small sample (n=30). Pilot design not powered for efficacy. Short 3-month follow-up. Open-label design. Single-site. Dosing varied based on dispensary pharmacist recommendations.
Questions This Raises
- ?What THC-to-CBD ratio is optimal for cancer pain?
- ?Can medical cannabis meaningfully reduce opioid doses in a larger trial?
- ?How do dispensary pharmacist recommendations compare to physician dosing?
Trust & Context
- Key Stat:
- Average daily cannabis doses: 34 mg THC + 17 mg CBD at 3 months
- Evidence Grade:
- Randomized design is a strength, but pilot sample size and open-label design limit conclusions.
- Study Age:
- Published in 2021.
- Original Title:
- A randomized trial of medical cannabis in patients with stage IV cancers to assess feasibility, dose requirements, impact on pain and opioid use, safety, and overall patient satisfaction.
- Published In:
- Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 29(12), 7471-7478 (2021)
- Authors:
- Zylla, Dylan M(3), Eklund, Justin, Gilmore, Grace(4), Gavenda, Alissa, Guggisberg, Jordan, VazquezBenitez, Gabriela, Pawloski, Pamala A, Arneson, Tom, Richter, Sara, Birnbaum, Angela K, Dahmer, Stephen, Tracy, Matthew, Dudek, Arkadiusz
- Database ID:
- RTHC-03647
Evidence Hierarchy
Participants are randomly assigned to treatment or placebo groups to test cause and effect.
What do these levels mean? →Frequently Asked Questions
Can medical cannabis help cancer patients reduce opioid use?
This small pilot trial showed trends in that direction, with a higher proportion of early cannabis users achieving opioid reduction and better pain control, but larger studies are needed.
How much cannabis did cancer patients use?
At 3 months, patients averaged 34 mg THC and 17 mg CBD daily, guided by licensed pharmacists at dispensaries.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-03647APA
Zylla, Dylan M; Eklund, Justin; Gilmore, Grace; Gavenda, Alissa; Guggisberg, Jordan; VazquezBenitez, Gabriela; Pawloski, Pamala A; Arneson, Tom; Richter, Sara; Birnbaum, Angela K; Dahmer, Stephen; Tracy, Matthew; Dudek, Arkadiusz. (2021). A randomized trial of medical cannabis in patients with stage IV cancers to assess feasibility, dose requirements, impact on pain and opioid use, safety, and overall patient satisfaction.. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 29(12), 7471-7478. https://doi.org/10.1007/s00520-021-06301-x
MLA
Zylla, Dylan M, et al. "A randomized trial of medical cannabis in patients with stage IV cancers to assess feasibility, dose requirements, impact on pain and opioid use, safety, and overall patient satisfaction.." Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2021. https://doi.org/10.1007/s00520-021-06301-x
RethinkTHC
RethinkTHC Research Database. "A randomized trial of medical cannabis in patients with stag..." RTHC-03647. Retrieved from https://rethinkthc.com/research/zylla-2021-a-randomized-trial-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.